Home › Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C
 

Keywords :   


Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C

2013-06-09 00:00:05| Biotech - Topix.net

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has granted priority review to the company's New Drug Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection.

Tags: of review treatment priority

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07Hurricane Beryl Graphics
03.07Farm Progress America, July 3, 2024
03.07Farm Progress America, July 3, 2024
03.07Hurricane Beryl Forecast Discussion Number 19
03.07Hurricane Beryl Wind Speed Probabilities Number 19
03.07Hurricane Beryl Public Advisory Number 19
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07Hurricane Beryl Forecast Advisory Number 19
More »